PSMA-trillium  (Synonyms: Felivotide mopaxetan)

PSMA-trillium (Felivotide mopaxetan) is a PSMA-targeted molecule that contains a highly specific PSMA-binding motif, an albumin-binding domain optimized for tumor uptake and retention, and a Macropa chelator conjugated to the α-emitter ²²⁵Ac. PSMA-trillium binds to albumin to prolong plasma retention time and binds to PSMA via its specific motif. ²²⁵Ac-PSMA-Trillium exhibits dose-dependent inhibition of LNCaP tumor growth in mice. PSMA-trillium can be used in research related to prostate cancer and metastatic castration-resistant prostate cancer^[1][2].

²²⁵Ac-PSMA-trillium maintains favorable stability for up to 48 h^[1].
²²⁵Ac-PSMA-trillium (0.114 kBq/mL) potently induces cytotoxicity in C4-2, a subclone of the prostate cancer cell line LNCaP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

²²⁵Ac-PSMA-Trillium (100-400 kBq/kg; intravenous injection; single dose) exhibits dose-dependent inhibition of LNCaP tumor growth and reduces tumor weight in male SCID mice, with higher tumor uptake and faster renal clearance compared to the control agent ²²⁵Ac-PSMA-SMOL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2371.44

C₁₀₆H₁₅₆IN₁₇O₃₄S

3036415-37-6

O=C([C@@H](NC(N[C@H](C(O)=O)CCCCNC(NC1=CC(C2=CN(N=N2)CCOCCOCCOCCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@H](C(O)=O)CCCCNC(CCCC3=CC=C(I)C=C3)=O)=O)=O)CCCCNC(NC4=CC=C(C=C4)CCOC5=CC(C(O)=O)=NC(CN6CCOCCOCCN(CC7=CC=CC(C(O)=O)=N7)CCOCCOCC6)=C5)=S)=O)=CC=C1)=O)=O)CCC(O)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zitzmann-Kolbe S, et al. Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)[J]. Cancer Research, 2024, 84(6_Supplement): 6033-6033.

  [2]. Hagemann U B, et al. Comparative evaluation of 225Ac-PSMA-Trillium with other 225Ac-PSMA-SMOL assets in a preclinical prostate cancer xenograft model[J]. Cancer Research, 2026, 86(7_Supplement): 7202-7202.